Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to JAK inhibitors versus adalimumab: a nationwide cohort study: comment on the article by Hoisnard et al

Similar Items

• Unexplored limitations in a randomized trial that examines efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: comment on the article by Merrill et al
  by: Qianyu Guo, et al.
  Published: (2025)
• Reassessing biomarker signatures in RA‐ILD and the impact of gender, environment, and disease activity: comment on the article by Wheeler et al
  by: Bi‐yun Yao, et al.
  Published: (2025)
• Systemic autoimmune rheumatic disease risk is associated with long‐term exposure to fine particulate matter: comment on the article by Geslin et al
  by: Shiuan‐Chih Chen, et al.
  Published: (2025)
• Insights on axial spondyloarthritis in multicenter cohorts of undiagnosed back pain patients: comment on the article by Maksymowych et al
  by: Qing Long, et al.
  Published: (2025)
• 2023 American College of Rheumatology/American College of Chest Physicians guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases: comment on the article by Johnson et al
  by: Julian Segan, et al.
  Published: (2025)